Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal

27 January 2010

Prometheus Laboratories, a US specialty pharmaceutical and diagnostic company, has entered an agreement with Swiss drug major Novartis to acquire exclusive rights to distribute, promote and sell Proleukin (aldesleukin) in the USA. The product is a recombinant human interleukin-2 for treatment in adults with metastatic melanoma and metastatic kidney cancer, which generated net sales of around $75 million in the USA in last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Biotechnology

Prometheus enters IBD deal with Takeda

7 October 2019

Company News Directory

Companies featured in this story

More ones to watch >

Company Spotlight

BeOne Medicines

A Nasdaq-listed oncology biotechnology company developing and commercializing cancer therapies across hematologic malignancies and solid tumors. BeOne Medicines operates a global development and commercial platform spanning North America, Europe and Asia.